NewGenIVF Shares Surge 179.65% After Key Acquisitions
By ATTN Desk · Editorial oversight: Sean Han
# NEWGENIVF GROUP LIMITED (NASDAQ: NIVF)
## Introduction
NEWGENIVF Group Limited is a fertility services provider with clinics in Thailand, Cambodia, and Kyrgyzstan. The company offers a range of assisted reproductive treatments, including in vitro fertilization (IVF), egg and sperm donation, surrogacy (where permitted), and related support services. Its objective is to improve access to infertility care for couples and individuals across Asia.
## Corporate Structure and Leadership
- **Founder & CEO**: Alfred Siu Wing Fung, with over a decade of experience in the fertility sector.
- **Executive Team**: Composed of IVF doctors, embryologists, nurses, and patient coordinators who provide clinical and patient support.
- **Management Experience**: The combined management experience exceeds ten years in the fertility and healthcare sectors.
- **Public Listing**: The company trades on NASDAQ under the ticker **NIVF**. On June 3, 2025, the share price closed at **\$4.81**, which reflects a **179.65%** increase from the prior close, with a trading volume of **9,400,512 shares**.
## Developments and News
- **February 28, 2025**
- Completed the acquisition of MicroSort Reproductive Technology, enhancing its sperm-sorting capabilities to improve treatment outcomes.
- **March 31, 2025**
- Terminated the binding term sheet with European Wellness Investment Holdings Limited, as the counterparty did not deliver the required draft audited financial statements for 2023–2024 by the agreed deadline. This action did not incur any penalties.
- **June 2, 2025**
- Filed Form 6-K with the U.S. Securities and Exchange Commission, reaffirming its status as a foreign private issuer and directing investors to a press release (Exhibit 99.1) for detailed disclosures.
## Financial and Strategic Analysis
| Metric | Value |
|---------------------------------------|-------------------|
| Market Capitalization (intraday) | \$1.29 million |
| Trailing 12-month Revenue | \$5.43 million |
| Net Income (TTM) | –\$0.525 million |
| Diluted EPS (TTM) | –\$293.10 |
| Profit Margin | –9.66% |
| Return on Assets | –17.99% |
| Return on Equity | –53.76% |
| Total Cash (mrq) | \$1.53 million |
| Total Debt (mrq) | \$0 |
| Levered Free Cash Flow (TTM) | \$0.548 million |
| Net Asset Increase (Sep 2024–Feb 2025)| +\$17 million |
| Net Asset Value per Share (Feb 2025) | \$2.16 |
| Debt as of Feb 2025 | \$50,000 |
- The completion of the MicroSort acquisition on February 28, 2025, expanded the company’s technology base.
- The termination of the European Wellness merger on March 31, 2025, prevented a potential 61.6% dilution of equity for existing shareholders.
- A cash position of \$1.53 million and negligible debt provide operational flexibility.
## Market Position and Industry Context
Asia’s fertility treatment market includes IVF, surrogacy, and family-balancing services. NEWGENIVF competes with regional clinics and emerging telemedicine platforms by offering on-site embryology laboratories and patient-centered care. Factors influencing demand include declining birth rates in key Asian markets, an increase in awareness of assisted reproduction, and regulatory changes in surrogacy jurisdictions.
## TL;DR
- On June 3, 2025, shares of NIVF closed at \$4.81, reflecting a **179.65%** gain from the previous session.
- The company finalized its MicroSort acquisition on February 28, 2025, and terminated the proposed reverse merger with European Wellness on March 31, 2025, due to unmet due diligence conditions.
- As of February 2025, net assets increased by \$17 million since September 2024, with a net asset value per share of \$2.16 and only \$50,000 in debt.
- Filed Form 6-K on June 2, 2025; management continues to focus on strategic alternatives and core IVF and surrogacy services in Asia.